Obesity is a chronic disease with a continuously rising prevalence that currently affects more
than half a billion people worldwide. Energy balance and appetite are highly regulated via …

Ever since Claude Bernards discovery in the mid 19th-century that a lesion in the floor of the
third ventricle in dogs led to altered systemic glucose levels, a role of the CNS in whole-body …

Aims To evaluate the safety, pharmacokinetics and pharmacodynamics of SAR425899, a
novel polypeptide, active as an agonist at both the glucagon‐like peptide‐1 receptor (GLP …

OBJECTIVE Roux-en-Y gastric bypass (RYGB) augments postprandial secretion of
glucagon-like peptide 1 (GLP-1), oxyntomodulin (OXM), and peptide YY (PYY) …

Several types of hormones exert control over appetite in humans. This narrative review
explores the effects of exercise and training on the concentrations of gastrointestinal …

Obesity and type 2 diabetes are a veritable global pandemic. There is an imperative to
develop new therapies for these conditions that can be delivered at scale to patients, which …

По данным Всемирной организации здравоохранения, в настоящее время около 422
млн людей во всем мире страдают сахарным диабетом. Стремительный рост …

Hypothalamic integration of gastrointestinal and adipose tissue-derived hormones serves as
a key element of neuroendocrine control of food intake. Leptin, adiponectin …

Bariatric surgery is currently the most effective therapeutic modality through which sustained
beneficial effects on weight loss and metabolic improvement are achieved. During recent …

Recently, oxyntomodulin (OXM) has emerged as a treatment option for type 2 diabetes
mellitus and obesity. In order to develop more promising novel OXM derivatives combining …